StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE), Merck (MRK) Treat First Patient in Avelumab Phase 3
April 5, 2016 8:22 AM
Merck (NYSE: MRK) and Pfizer (NYSE: PFE) announced the treatment of the first patient in a Phase III study of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
April 6, 2016 10:42 AM
Pfizer (PFE), Merck KGaA Treat First Patient in Avelumab Phase 3 in RCC Setting
April 5, 2016 8:10 AM
Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
April 5, 2016 8:03 AM
Merck KGaA, Darmstadt, Germany, and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and INLYTA® in Renal Cell Carcinoma
April 5, 2016 8:02 AM
After rally, earnings gloom takes hold on Wall Street
April 5, 2016 7:32 AM
